Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Acumen Pharmaceuticals Inc’s stock clocked out at $1.63, down -1.21% from its previous closing price of $1.65. In other words, the price has decreased by -$1.21 from its previous closing price. On the day, 0.54 million shares were traded. ABOS stock price reached its highest trading level at $1.73 during the session, while it also had its lowest trading level at $1.57.
Ratios:
To gain a deeper understanding of ABOS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.43 and its Current Ratio is at 10.43. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on July 26, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when Meisner Derek M bought 3,418 shares for $1.59 per share.
Siemers Eric bought 3,219 shares of ABOS for $5,118 on Jan 21 ’25. On Jan 21 ’25, another insider, Barton Russell, who serves as the Officer of the company, bought 2,914 shares for $1.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABOS now has a Market Capitalization of 99131712 and an Enterprise Value of -72424960.
Stock Price History:
The Beta on a monthly basis for ABOS is 0.01, which has changed by -0.4891641 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, ABOS has reached a high of $5.09, while it has fallen to a 52-week low of $1.53. The 50-Day Moving Average of the stock is -23.36%, while the 200-Day Moving Average is calculated to be -39.30%.
Shares Statistics:
It appears that ABOS traded 296.49K shares on average per day over the past three months and 359430 shares per day over the past ten days. A total of 60.08M shares are outstanding, with a floating share count of 43.86M. Insiders hold about 26.99% of the company’s shares, while institutions hold 64.41% stake in the company. Shares short for ABOS as of 1735603200 were 1555225 with a Short Ratio of 5.25, compared to 1732838400 on 1385196. Therefore, it implies a Short% of Shares Outstanding of 1555225 and a Short% of Float of 3.4799999999999995.
Earnings Estimates
The stock of Acumen Pharmaceuticals Inc (ABOS) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$1.0 and -$1.51 for the fiscal current year, implying an average EPS of -$1.32. EPS for the following year is -$1.53, with 3.0 analysts recommending between -$1.34 and -$1.69.
